Core Viewpoint - Tianyu Co., Ltd. focuses on serving large multinational pharmaceutical companies and original research drug companies, aiming to deepen its "customer first" strategic goal [1] Group 1: Business Strategy - The company has provided active pharmaceutical ingredients (APIs) for 8 original research drug varieties and aims to add 1-2 new commercialized APIs annually with original research drug companies [1] - The company seeks to strengthen existing partnerships with original research clients while expanding its customer base to enhance its competitive advantage in APIs [1] Group 2: Strategic Partnerships - Tianyu has established long-term stable strategic partnerships with internationally renowned pharmaceutical companies such as Novartis, Sanofi, and Daiichi Sankyo [1] - The scope of cooperation has expanded from sartans APIs to non-sartan APIs, off-patent drugs, and innovative drug CDMO projects, indicating an increase in both depth and breadth of collaboration [1]

Group 1 - The core viewpoint is that the pesticide industry is currently at the bottom of its cycle, facing short-term pressures from repeated capacity construction and declining product prices [1] - The company emphasizes its commitment to technological innovation and increased R&D investment, aiming to launch market-promising patented and self-developed products in the future [1] - The company plans to strengthen its core competitiveness through optimizing product structure and expanding domestic and international market share, ensuring steady long-term value growth [1] Group 2 - The company is highly attentive to capital market dynamics and market value management, intending to improve and optimize its market value management work in compliance with legal regulations [1] - Future strategies will be aligned with the company's strategic planning, financial status, and market environment [1]